poisar

Stocks · News reference

Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037

Benzinga Newsdesk

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva Pharmaceuticals Inc.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AUPHTEVA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. James Halley

    Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?

    Teva Pharmaceuticals is executing a successful turnaround strategy, shifting from generics to higher-margin branded therapies. Its three key drugs (Austedo, Ajovy, Uzedy) grew sales 33% year-over-year to $1.1 billion in Q3, while gross margins improved to 55.5%. The company has paid down $12 billion in debt since 2019 and received investment-grade ratings. However, overall Q3 revenue declined 2% due to generic drug competition, and the company faces headwinds from commoditized generics. Despite recent gains, the stock trades at less than 21x forward earnings.

    TEVA